UK Reveals Seven Partners Whose New Drug Approvals It Will Recognize
Executive Summary
The UK regulator, the MHRA, says that while it will recognize drug approvals granted in the EU and a selection of other countries, it will remain a “sovereign regulator” with the ability to reject applications if they don’t meet its standards.
You may also be interested in...
UK’s New International Recognition Procedure A ‘Win-Win’ For Stakeholders
Companies wanting to use the new accelerated procedure will be paying more than £68,000 for the privilege, and will have to inform the UK medicines agency of any divergent decisions by reference regulators.
UK’s New International Recognition Procedure A ‘Win-Win’ For Stakeholders
Companies wanting to use the new accelerated procedure will be paying more than £68,000 for the privilege, and will have to inform the UK medicines agency of any divergent decisions by reference regulators.
UK’s New International Recognition Procedure A ‘Win-Win’ For Stakeholders
Companies wanting to use the new accelerated procedure will be paying more than £68,000 for the privilege, and will have to inform the UK medicines agency of any divergent decisions by reference regulators.